-
InventisBio Raises USD 308M in Shanghai STAR IPO, Valued at USD 1.54B
•
China-based biotech firm InventisBio (SHA: 688382) has completed an initial public offering (IPO) of 115 million shares on the Shanghai Stock Exchange’s Science and Technology Innovation Board (STAR). The shares were priced at RMB 18.12 (USD 2.68) each, raising a total of RMB 2.08 billion (USD 308 million) and valuing…
-
NMPA Releases 56th Batch of GQCE Reference Drugs, Including 14 Injectables
•
The National Medical Products Administration (NMPA) has released the 56th batch of reference drugs for generic quality consistency evaluation (GQCE) work, including 14 injectables among a total of 74 new specifications. Batch DetailsThe latest batch comprises 74 new drug specifications, with 14 being injectables. This marks the continued expansion of…
-
MobiDrop Raises USD 14.8M in Series A+ to Expand Single-Cell Product Pipeline
•
China-based MobiDrop (Zhejiang) Co., Ltd has reportedly raised close to RMB 100 million (USD 14.8 million) in a Series A+ financing round led by LYFE Capital. Existing investor Source Code Capital and a government-led fund also participated. Funding UseProceeds will support the expansion of MobiDrop’s single-cell product pipeline, research and…
-
Luye Pharma’s LY01005 Meets Phase III Trial Goals in Breast Cancer Treatment
•
China-based Luye Pharma Group (HKG: 2186) announced that its Phase III clinical study for LY01005 in breast cancer treatment has successfully met pre-set endpoints. The study demonstrated that LY01005 effectively controls serum estradiol to postmenenopausal levels, with clinical efficacy comparable to a control drug, achieving a non-inferiority standard. Study DetailsThe…
-
ZGC Shuimu Medtech Raises RMB 100M in Series A+ Round Led by Yijing Capital
•
Beijing-based ZGC Shuimu Medical Technology Services Group, China’s first private third-party medical device testing institution, has reportedly raised RMB 100 million (USD 18.8 million) in a Series A+ financing round. The round was led by Yijing Capital and Green Pine Capital Partners. This follows the company’s Series A financing round…
-
Innovita Biological Technology’s IPO Raises USD 131.3M for POCT Expansion
•
Innovita Biological Technology Co., Ltd, a Beijing-based point-of-care testing (POCT) specialist, is set to make an initial public offering (IPO) of 34.02 million shares on Shanghai’s Sci-Tech Innovation Board (STAR). The shares are priced at RMB 26.06 (USD 3.86) each, with the listing expected to raise RMB 887 million (USD…
-
Fidia Farmaceutici’s Hyalubrix 60 Shows Promise in Treating Arthropathy at Hainan Hospital
•
Italy-based Fidia Farmaceutici S.p.A announced that its Hyalubrix 60, a prefilled syringe with sodium hyaluronate solution for intra-articular injection, has successfully completed treatment in four patients at Hainan General Hospital’s Lecheng branch. Product ProfileHyalubrix 60 is designed to restore the viscoelastic properties of knee and hip synovial fluid. It serves…
-
Linno Pharmaceuticals Raises USD 14.78M for Blood-Brain Barrier Drug Delivery Tech
•
Shanghai-based rare disease specialist Linno Pharmaceuticals Inc. has reportedly raised close to RMB 100 million (USD 14.78 million) in angel and pre-Series A financing rounds. The round was led by Puhua Capital, with contributions from Zhangke Lingyi Investment. Funding UseProceeds will support upgrades in blood-brain barrier-crossing macromolecular drug delivery technology…
-
Frontier Biotech Raises USD 51.4M to Advance COVID-19 Drug FB2001
•
China-based Frontier Biotechnologies Inc. (SHA: 688221) announced plans to raise RMB 270 million (USD 51.4 million) through a private placement to support the development of its COVID-19 drug candidate FB2001. The funding will be used for a Phase I clinical study, global Phase II/III trials, and quality and process studies.…
-
Curatia Medical Raises Tens of Millions in Funding Co-led by Hidea Investment
•
Curatia Medical Ltd, a vascular interventional therapy developer with operations in Silicon Valley, California, and Suzhou, China, has reportedly raised tens of millions of renminbi in its latest financing round, co-led by Hidea Investment. Company BackgroundFounded in 2015, Curatia specializes in biomaterials, machinery, coatings, metal weaving, extrusion, abrasives, and other…
-
Novaremed AG Licenses NRD.E1 to NeuroFront for Greater China Development
•
Switzerland-based Novaremed AG has entered into a licensing agreement with China’s NeuroFront (Shanghai) Co., Ltd, granting NeuroFront exclusive rights to develop, commercialize, and manufacture NRD.E1 in Greater China, including mainland China, Hong Kong, Macau, and Taiwan. In exchange, Novaremed will receive upfront and milestone payments totaling USD 130 million. Drug…
-
Ascentage Pharma’s Olverembatinib Receives Health Canada Approval for Phase Ib Study
•
Suzhou-based Ascentage Pharma (HKG: 6855) announced that it has received approval from Health Canada to conduct a Phase Ib clinical study of its third-generation BCR-ABL-targeted tyrosine kinase inhibitor (TKI), olverembatinib (HQP1351), for drug-resistant chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL). Study DetailsThe open-label, multi-center, randomized, global…
-
Junshi Biosciences’ Toripalimab Receives EC Orphan Drug Designation for NPC
•
China-based Junshi Biosciences (HKG: 1877, SHA: 688180) announced that its PD-1 inhibitor Toripalimab (trade name: Tuoyi) has received orphan drug designation (ODD) from the European Committee (EC) for the treatment of nasopharyngeal carcinoma (NPC). This marks the sixth ODD for Toripalimab in the US and Europe, following previous designations for…
-
Yifeng Pharmacy Chain to Establish New Company with Tangshan Deshuntang
•
China-based Yifeng Pharmacy Chain Co., Ltd (SHA: 603939) announced that its subsidiary, Shijiazhuang Xinxing Pharmacy Chain Co., Ltd, will establish a new company with Tangshan Deshuntang Pharmaceutical Chain Co., Ltd. The new entity, tentatively named Tangshan Xinxing Deshuntang Pharmaceutical Chain Co., Ltd, will take over all business and assets of…
-
Ji Xing Pharmaceuticals Enrolls First Patient in OC-01 Phase III Study for Dry Eye
•
Shanghai-based Ji Xing Pharmaceuticals, backed by RTW Investments, announced that the first patient has been enrolled in a Phase III clinical study for its OC-01 (varenicline) nasal spray in China. The study aims to evaluate the efficacy and safety of OC-01 in treating dry eye and neurotrophic keratopathy. Drug ProfileOC-01…
-
Gan & Lee Pharmaceuticals Doses First Patient in GZR18 Phase II Study for Diabetes and Obesity
•
China-based Gan & Lee Pharmaceuticals (SHA: 603087) announced that the first patient has been dosed in a Phase II clinical study for its Category 1 biologic product GZR18, a novel glucagon-like peptide-1 (GLP-1) receptor agonist designed for once-weekly administration. Study DetailsThe Phase Ib/IIb study will evaluate the safety, tolerability, pharmacokinetics,…
-
Sinopep-Allsino Biopharm’s SPN0103-009 Receives NMPA Approval for Diabetes and Obesity Clinical Study
•
China-based Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd announced that it has received approval from the National Medical Products Administration (NMPA) to conduct a clinical study of its injectable SPN0103-009 for the treatment of type 2 diabetes and obesity. Drug ProfileSPN0103-009 is a novel, long-acting GLP-1 peptide analog designed for improved stability,…
-
Lepu Biopharma’s Pucotenlimab Receives Conditional NMPA Approval for MSI-H/dMMR Tumors
•
The National Medical Products Administration (NMPA) has granted conditional market approval to Lepu Biopharma Co., Ltd’s pucotenlimab (HX008), a programmed death 1 (PD-1) targeted humanized IgG4 monoclonal antibody (mAb). The drug is indicated for microsatellite instability-high/deficient mismatch repair (MSI-H/dMMR) expressing tumors in two patient groups: (1) those with advanced colorectal…
-
Fosun Pharmaceutical to Raise USD 662M via Share Issue for Drug Development and API Base
•
China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced plans to issue 128,144,927 A shares at RMB 42 (USD 6.20) per share. The proceeds, totaling RMB 4.48 billion (USD 662 million), will be allocated to clinical studies of novel drugs, licensing deals, product launches, and the construction…
-
Tris Pharma and Pediatrix’s Methylphenidate Tablet, Ipsen’s Triptorelin Injection Awarded Priority Review by CDE
•
The Center for Drug Evaluation (CDE) website shows that US-based Tris Pharma and Pediatrix Therapeutics’ methylphenidate hydrochloride sustained release chewable tablets, along with Ipsen Pharma’s injectable pamoic acid triptorelin injection, have been granted priority review status. The drugs are recognized for aligning with new pediatric drug varieties, dosage forms, and…
